|Chemical and physical data|
|Molar mass||275.217 g/mol|
|3D model (JSmol)|
|(what is this?)|
BD-1047 is a sigma receptor antagonist, selective for the σ1 subtype. It has effects in animal studies suggestive of antipsychotic activity and may also be useful in the treatment of neuropathic pain.
More recent studies also suggest a novel role for BD-1047 in attenuating ethanol-induced neurotoxicity in vitro, and additional research is being conducted on this compound as a possible pharmacotherapy for alcohol use disorder (AUD) 
- Skuza G, Rogóz Z (2006). "Effect of BD 1047, a sigma1 receptor antagonist, in the animal models predictive of antipsychotic activity". Pharmacological Reports : PR. 58 (5): 626–35. PMID 17085854.
- Roh DH, Kim HW, Yoon SY, Seo HS, Kwon YB, Kim KW, Han HJ, Beitz AJ, Na HS, Lee JH (November 2008). "Intrathecal injection of the sigma(1) receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain". Anesthesiology. 109 (5): 879–89. doi:10.1097/ALN.0b013e3181895a83. PMID 18946301.
- Reynolds AR, Saunders MA, Prendergast MA (2016). "Ethanol Stimulates Endoplasmic Reticulum Inositol Triphosphate and Sigma Receptors to Promote Withdrawal-Associated Loss of Neuron-Specific Nuclear Protein/Fox-3". Alcohol Clin Exp Res. 40 (7): 1454–61. PMID 27177604.
|This pharmacology-related article is a stub. You can help Wikipedia by expanding it.|